In reply: We would like to thank Hassed and colleagues for their comments on the “therapeutic footprint” and their questions about locating specific therapies within the model. While it was outside the scope of our article to critically analyse different treatments using the model (as benefits and risks will vary from patient to patient), we would like to direct Hassed et al to a more detailed consideration of the risks and benefits of chemotherapy.1
The full article is accessible to AMA
members and paid subscribers.
Login to MJA or subscribe now.
- 1 Southern Adelaide Palliative Services, Adelaide, SA.
- 2 Department of Medical Oncology, Flinders Medical Centre, Adelaide, SA.
- 3 Department of Palliative and Supportive Services, Flinders University, Adelaide, SA.
Correspondence: christine.sanderson@rgh.sa.gov.au
- 1. Mileshkin L, Rischin D, Prince HM, Zalcberg J. The contribution of cytotoxic chemotherapy to the management of cancer [Comment on: Clin Oncol (R Coll Radiol) 2004; 16: 549-560.] Clin Oncol (R Coll Radiol) 2005; 17: 294.
Online responses are no longer available. Please refer to our instructions for authors page for more information.